CDNA CareDx, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1217234 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.9%
TTM net income YoY111.7%
TTM EPS YoY85.2%
Revenue 3-yr CAGR18.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin23.4%
Net margin25.9%
FCF margin—
EBITDA margin27.0%
Returns
ROE33.0%
ROA24.0%
ROIC (approx.)53.4%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets27.1%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.54x
Accruals ratio11.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $139.36M | $131.95M | $117.70M | $108.39M | $100.06M | $86.68M | $84.69M | $86.58M |
| R&D expense | $21.32M | $22.38M | $21.42M | $19.31M | $16.77M | $16.83M | $18.52M | $16.62M |
| SG&A expense | $37.99M | $40.91M | $30.48M | $28.68M | $28.43M | $27.68M | $22.77M | $32.35M |
| Operating income | $8.11M | $113.22M | $1.20M | -$6.04M | -$246,000 | -$11.12M | -$13.37M | $74.69M |
| Pretax income | $10.69M | $114.52M | $2.78M | -$3.76M | $1.66M | -$8.69M | -$10.29M | $87.87M |
| Income tax | -$8.60M | $3.88M | -$32,012 | $345,000 | -$15,000 | -$117,000 | $58,000 | $171,000 |
| Net income | $19.29M | $110.64M | $2.81M | -$4.11M | $1.68M | -$8.57M | -$10.35M | $78.01M |
| EBITDA | $15.32M | $116.03M | $5.10M | -$2.16M | $3.57M | -$7.40M | -$9.77M | $78.05M |
| EPS (basic) | 0.37 | 2.15 | 0.05 | — | 0.03 | -0.16 | -0.19 | — |
| EPS (diluted) | 0.35 | 2.07 | 0.05 | — | 0.03 | -0.16 | -0.19 | — |
| Weighted avg. shares (diluted) | 54.98M | 53.42M | 53.13M | — | 53.74M | 54.30M | 55.26M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $250.48M | $373.64M | $77.92M | $65.43M | $91.44M | $68.21M | $88.75M | $115.27M |
| Short-term investments | $0 | $0 | $109.25M | $111.78M | $102.78M | $118.04M | $142.17M | $145.96M |
| Receivables | $47.73M | $34.38M | $44.59M | $42.63M | $47.84M | $67.36M | $71.48M | $64.61M |
| Inventory | $9.14M | $6.98M | $26.40M | $26.70M | $28.33M | $27.91M | $22.93M | $19.50M |
| Current assets | $321.30M | $429.22M | $269.39M | $257.13M | $300.28M | $307.30M | $350.24M | $351.83M |
| PP&E, net | $27.01M | $26.84M | $33.16M | $32.97M | $30.84M | $31.93M | $32.73M | $33.55M |
| Goodwill | $121.71M | $35.97M | $40.34M | $40.34M | $40.34M | $40.34M | $40.34M | $40.34M |
| Intangibles | $139.78M | $18.56M | $32.10M | $31.96M | $33.45M | $36.04M | $37.25M | $38.18M |
| Total assets | $641.46M | $532.99M | $411.06M | $413.23M | $432.31M | $444.26M | $489.64M | $491.05M |
| Current liabilities | $138.97M | $93.70M | $79.15M | $89.85M | $99.04M | $93.18M | $85.28M | $89.37M |
| Total liabilities | $174.00M | $107.39M | $97.53M | $110.13M | $121.17M | $116.89M | $110.29M | $112.62M |
| Shareholders' equity | $467.46M | $425.60M | $313.54M | $303.10M | $311.14M | $327.37M | $379.35M | $378.43M |
| Shares outstanding | 52.46M | 51.48M | 51.27M | 50.92M | 51.41M | 53.22M | 55.46M | 54.77M |
| Cash flow statement | ||||||||
| Operating cash flow | $12.72M | $30.60M | $4.33M | $21.36M | $37.36M | $9.89M | -$26.58M | $21.89M |
| Capital expenditure | $1.61M | $1.86M | $3.82M | — | $1.30M | $1.01M | $1.63M | — |
| Free cash flow | $11.10M | $28.75M | $514,000 | — | $36.05M | $8.89M | -$28.21M | — |
| Investing cash flow | -$147.88M | $280.59M | $11.06M | -$34.91M | $12.35M | $23.40M | $1.32M | -$2.11M |
| Financing cash flow | $12.90M | -$15.50M | -$2.91M | -$12.46M | -$26.48M | -$53.81M | -$643,000 | -$903,000 |
| Depreciation & amortization | $7.20M | $2.81M | $3.90M | $3.88M | $3.81M | $3.72M | $3.60M | $3.36M |
| Stock-based compensation | $9.65M | $10.65M | $9.80M | $8.09M | $8.42M | $9.42M | $8.93M | $26.20M |
| Share buybacks | $0 | — | — | $12.21M | $25.56M | $50.00M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.